RECURSION PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$30.72 million for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-12.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2021-05-12
- RECURSION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2021-03-31 was -$30.72M.
- RECURSION PHARMACEUTICALS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2020-03-31 was -$18.42M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month |
|---|---|
| 2021-03-31 | -$30.72M 10-Q · filed 2021-05-12 |
| 2020-03-31 | -$18.42M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |